Module

Follicular Lymphoma: State of the Art

Source: Advances in the Treatment of Lymphoproliferative Malignancies: Promising Directions in Mantle Cell Lymphoma, Follicular Lymphoma, and Waldenstrom’s Macroglobulinemia

Follicular Lymphoma: State of the Art


CME Program Director: James O. Armitage, MD

Faculty:

  • Owen A. O'Connor, MD, PhD

CME CREDIT INFORMATION

Release Date: 09/28/07

Expiration Date: 09/27/08


Physicians: maximum of 0.5 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Articulate the various lymphoma classification schemes
  • Recall the use of rituximab in the treatment of follicular lymphoma
  • List novel compounds of interest in the treatment of follicular non-Hodgkin’s lymphoma

Topics covered include:

  • Introduction
  • Diagnosis of FL
  • Prognosis of FL
  • Principles of Treatment: Overview
  • Novel Targets
  • Bortezomib in Relapsed Indolent NHL and Mantle Cell Lymphoma
  • Future Directions in FL
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by University of Nebraska Medical Center, Center for Continuing Education and Clinical Care Options, LLC.

Educational grant provided by: